secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002690
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma reports ~$333M cash, luvelta data in ovarian cancer, AML, NSCLC trials planned
--------------------------------------------------------------------------------

- Preliminary cash, equivalents, marketable securities ~$333M as of Dec 31, 2023; 0.7M shares of Vaxcyte stock valued ~$42M, funding into 2H2025.
- Updated luvelta data in ovarian cancer: improved clinical outcomes and tolerability vs historical chemo; prophylactic G-CSF reduced neutropenia/dose delays.
- Luvelta + bevacizumab showed clinical activity regardless of FolRα expression; preclinical NSCLC data showed single-dose activity and benefit with PD-1 blockade.
- REFRαME-O1 registration trial in platinum-resistant ovarian cancer enrolling, Part 1 completion expected 1H2024, ~140 sites by end of 2024.
- REFRαME-P1 trial initiation in pediatric CBF/GLIS AML planned 1H2024; IND submission in NSCLC planned 1H2024; endometrial cancer development ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/0000950170-24-002690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/stro-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer